Preclinical toxicology of small molecule drugs developed for cancer and other indications

Active Indefinite Delivery Contract Awarded Last action

Contract number
75N91022D00016
Awardee
Awarding agency
Task orders
4 $2,429,141 obligated

Award facts

Opportunity
Combined order value
  • $2,429,141 Current, with exercised options
  • $3,747,206 Potential, with all options
Last date to order 58% complete
IDV ceiling 25% used
$9,838,435.00
Award type
Single award
Who can order
Only the awarding agency
Set-aside
No set-aside
Competition
Full and Open Competition · 5 offers Negotiated Proposal / Quote
Pricing
Order Dependent (IDV only)
Legislative mandates

Award details come from SAM.gov/FPDS.

About this IDV

The National Cancer Institute awarded a single-award indefinite-delivery contract to IIT Research Institute for preclinical toxicology of small molecule drugs developed for cancer and other indications, with a ceiling of $9,838,435 and an award date of September 26, 2022. The contract extends through September 25, 2029.

Work is performed at IIT Research Institute's Chicago, Illinois location. The IDIQ covers non-GLP and GLP toxicology studies in mice and dogs supporting investigational new drug development across cancer and other therapeutic indications.

The originating solicitation was posted as a pre-solicitation on April 6, 2020, with a due date of April 21, 2020. No set-aside was used.

Recent task-order activity under this vehicle includes a $1,790,042 cost-plus-fixed-fee delivery order for toxicology studies in mice and dogs administered MTX-531 awarded June 12, 2024 (completion June 11, 2025); a $68,323 firm fixed-price delivery order for toxicology studies in mice administered MTX-531 awarded February 9, 2026 (completion May 9, 2026); and a $2,708 cost-plus-fixed-fee contract orientation and kickoff meeting awarded September 26, 2022 (completion April 25, 2025). All recent orders have been issued by the National Cancer Institute and performed in Chicago, Illinois.

IIT Research Institute is a nonprofit contract research organization and wholly-owned subsidiary of Illinois Institute of Technology. The organization conducts good laboratory practice and non-GLP toxicology studies in rodent and canine models, dose range-finding evaluations, and safety assessments for small molecule drug candidates.

Task orders

Transactions

Action Obligated Date
Other Administrative Action P00004 · EO14398; preclinical toxicology of small molecule drugs developed for cancer and other indications $0
Other Administrative Action P00003 $0
Other Administrative Action P00002 $0
Other Administrative Action P00001 $0
Original award $0

Quick answers

Who was awarded contract 75N91022D00016?

75N91022D00016 was awarded to IIT Research Institute by National Cancer Institute (National Institutes of Health) on September 26, 2022.

How much is contract 75N91022D00016 worth?

Orders under 75N91022D00016 have obligated $2,429,141. Their combined potential value, with all options, is $3,747,206. 75N91022D00016's own ceiling is $9,838,435.

How many orders have been placed under contract 75N91022D00016?

4 orders have been placed under 75N91022D00016, the latest on February 9, 2026.

Who can order from contract 75N91022D00016?

75N91022D00016 is a single award indefinite delivery contract. Only the awarding agency can place orders on it.

Was contract 75N91022D00016 competed?

The extent of competition for 75N91022D00016 was full and open competition. The government received 5 offers.

On GovTribe

See this IDV's full record

  • Every order and transaction
  • The awardee's other awards and teaming partners
  • Similar IDVs and recompete opportunities
  • Ask GovTribe AI about this IDV